In Brief: FDA's Oncologic Drugs Advisory Committee
FDA's Oncologic Drugs Advisory Committee: Will meet Dec. 14 to discuss Bryant Corp.'s Luzenac sterile aerosol talc (NDA 20-587) for treatment of malignant pleural effusion and NeoRx' monoclonal antibody OncoTrac (PLA 94-0308) for small-cell lung cancer. Boehringer Ingelheim retains exclusive marketing rights to OncoTrac outside North America, and NeoRx is in a marketing alliance with DuPont Merck for the North American rights to the product. The advisory committee also will discuss FDA oncology initiatives. The meeting will take place at the Bethesda Holiday Inn, Bethesda, Md., beginning at 8 a.m...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth